Leuprorelin - Tolmar
Alternative Names: Eligard; FENSOLVI; LA 2575; Leuprogel®; Leuprolide acetate - Tolmar; SOT-375; TOL-2506Latest Information Update: 05 Nov 2023
At a glance
- Originator QLT USA
- Developer MediGene AG; Tolmar
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Precocious puberty; Prostate cancer
- Phase III HER2 negative breast cancer
- Discontinued Endometriosis
Most Recent Events
- 26 Jan 2023 Phase-III clinical trials in HER2-negative-breast-cancer (Combination therapy) in Puerto Rico, Mexico (SC, Injection) (NCT04906395)
- 13 Dec 2022 Tolmar initiates a phase III trial for Breast cancer (Combination therapy) in USA (Injection) (NCT05645536)
- 08 Oct 2021 Leuprorelin is no more licensed to Sanofi in Canada